


DOVERTOR OFFICE

## Anti-CTLA4 Abs #25, #26, and #29 defined three distinct epitopes on CTLA4

1.2 0.8 0.9 0.6 0.4

CTLA4 point mutant	Antibody #25					
Mock	0.165					
wT	1.17					
T67	0.935					
Q62	1.1					
R85	0.96					
063	0.986					
R36	0.52					
S64	1.07					
165	1,19					
L81	1,14					
T45	0.948					
E46	0.811					
D62	0.985					
CTLA4-la	0.996					
DME	0.14					



Antibody #26






Fig 3A Proliferation






Fig. 4A Proliferation



IL-2 Production

IL-2 (pg/ml) 1310 720 594 358 400 715 875 982 982 317






Figure 5

## FACS Competition Using FITC-Labeled CTLA4-26B with Cold CTLA4-26B and Humanized IgG1/K

		•								
	Name	Cell Li	ne	Primary	Ab		С	ompetitor		
		CHO.C	TLA4	FITC-CTLA	4-26B		Cole	CTLA4-2	26B	
	052199.00			125 ng				2000 ng		
	052199.00			1				1000 ng		
	052199.00							500 ng		
	052199.00							250 ng		
	052199.00			1				100 ng		
	032177.00	~						IgG1/κ		
	052199.00	16		İ				2000 ng		
	052199.00							1000 ng		
	052199.00			i				500 ng		
	052199.00			1				250 ng		
	052199.0			1				100 ng		
	052199.0			N/				none		
	052199.0		,	none				none		
	052199.0		B7 1	125 ng				none		
	052199.0			none	•			none		
110	*********	v								
19.0 A V			Fig			Fig				
A			6B	§ <del>1</del>			81			
3.1	8 <sub>1</sub>		00	e :		- GC	°1	10.		- 1
1113	8-1 W	i.		용 .	a		욳-	1.40		l l
l. A	~	Make Some As		1 / 1	March Mr.		1	11 34	MA.	1
1285	g.1	L. MWINE		. 84	A MANAGER	.	<u>,,≊1</u>	1 151	f = f	
	Counts 120 180	AL MILE	i I	Counts	A MANAGE I	1 1	Counts 120 180	1 13	1.3	<b>k</b>
	38	MAN	9 1 .	884 /	CARRY!	\	884	1 %		1
15	-1 /	WAY SAIN	4	1 1 11	STAN A	h.	1	1 1	, pd	\ \
-3	2-1	Company of the	M I	2 Jan	A VIN	1	8-	£	Se della	٩
- 4	Section Section	Britis P. 17	181	A STATE OF THE STA	Allen Sold	13	ie.	A Pharman	Sel.	
TU TO	O Transmit	The state of the s	A CONTRACTOR OF THE PARTY OF TH	100 101	10 <sup>2</sup> 10 <sup>3</sup>	104	100	101	102 103	104
199	100 101	10 <sup>2</sup> 10 <sup>3</sup> FL1-H	104	100 101	10 <sup>2</sup> 10 <sup>3</sup> FL1+H	10	10	10	10 <sup>2</sup> 10 <sup>3</sup> FL1-H	
1000										
Jest .			Gate I	Key Name	Parameter	Gate	Key	Name	Parameter	Gate
	Key Name 052199.0	Parameter 16 FL1-H	No Gate	Name 052199.016	FL1-H	No Gate		052199.016	FL1-H	No Gate
	052199.0		No Gate	052199.017	FL1-H	No Gate		052199.017	FL1-H	No Gate
	052199.0		No Gate	052199.006	FL1-H	No Gate		052199.018	FL1-H	No Gate
	052199.0	02 FL1-H	No Gate	052199.007	FL1-H	No Gate	de la constante de la constant	052199.019	FL1-H	No Gate
	052199.0		No Gate	052199.008	FL1-H	No Gate				
	052199.0	04 FL1-H	No Gate	052199.009	FL1-H	No Gate				
					e	No Cote				

052199.010

FL1-H

No Gate

052199.005

FL1-H

No Gate





Figure 7

Fig 8A

Jurkat CTLA4 NEGATIVE cell line



E Fig.183

Jurkat CTLA-4 POSITIVE cell line




Figure 9

HuCTLA4 - VH

CGAGGCCCCCGCACGCTATGATGAAGAGAGGCTATGCTATGGACTACTGGGGACAAGGAR GPPHAMMKRGGYAMD $_{\rm Y}$ WGQG




Figure 11